HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia

Deal Would Include Hikma Acquiring GSK’s 91.2% Holding

Executive Summary

With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.

You may also be interested in...



EU Business Round-Up: BioGaia Creates Investment Arm, Boiron Grows In Spain, GSK Ends Hikma Talks

Latest European consumer health business news: BioGaia sets up an investment arm to identify interesting start-ups, France's Boiron expands its Spain offering with Iprad deal, and GSK ends talks with Hikma over the sale of its Egyptian OTC business.

Top 20 Consumer Health Deals 2020: Private Equity And OTC Exits Drive M&A

HBW Insight reveals the biggest consumer health deals of 2020, and identifies growing private equity investment, portfolio streamlining by major players and pharma firms exiting OTC as the major drivers of M&A activity.

Hikma Suspends Roll-Out Of Advair Rival

Hikma has temporarily stopped the roll-out of its rival to Advair Diskus in the US after it filed an amendment to its ANDA over packaging controls.

Related Content

Related Companies

UsernamePublicRestriction

Register

RS150941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel